Abstract
This Correspondence relates to "An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy" (J Mol Diagn 2008, 10:177–180).
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Exons / genetics*
-
Fusion Proteins, bcr-abl / genetics*
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Mutagenesis, Insertional*
-
Phosphotransferases / chemistry*
-
Phosphotransferases / genetics*
-
Piperazines / therapeutic use
-
Protein Structure, Tertiary / genetics
-
Pyrimidines / therapeutic use
-
Transcription, Genetic
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate
-
Phosphotransferases
-
Fusion Proteins, bcr-abl